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Abstract: This study analyzes the Spanish regulations on Biomedical research, with special reference 
to the Act of July 3, 2007, inspired by the instruments adopted by the Council of Europe and the 
European Union as well as in the domestic laws of the United States and the United Kingdom, which are 
pioneers in the field. This is an advanced law which regulates basic character research and the most 
controversial issues, both in law and ethical spheres, especially in stem cells research, allowing, with 
certain limits, the use of embryos, human fetuses, ovocytes and pre-embryos. To complement this 
approach, the study also analyzes the legal regime applied to clinical trials for drugs and health products. 
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I. INTRODUCTION 
 
For over twenty years, Spain has been the world’s leader in the donation and 
transplant of organs. This is because the Spanish model includes a set of legal measures 
to improve organ donation
3
, and the application has been recommended by the OMS in 
different regions of the world. From a future perspective, there are regulations regarding 
artificial insemination and biomedical research in humans, consistent with the practice 
in most advanced countries, where the principlism, known as the Georgetown approach 
to bioethics, is applied and is based on the work of the National Commission for the 
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Protection of Human Subjects of Biomedical and Behavioral Research (Ainslie 2003: 
pp. 2099-2100). 
 
The principlism is best used to address ethical and legal issues raised by the 
human experimentation method. The four basic principles in which it is inspired, 
respect for autonomy, which means taking into account the ability of people to make 
decisions, non-maleficence to avoid damages, charity as specified in the requirement to 
provide benefits with application of prejudice -benefit rule, and justice, which is the 
fairness in the distribution of benefits and risks (Beauchamp and Childress 2013: pp. 
13-29; Beauchamp 1994: pp. 3-6; Ainslie 2003: p. 2100). These principles are linked to 
human rights (Peces-Barba 1994: pp. IX-XI) and inspire statements and codes of 
conduct and professional ethics, which in turn influence international instruments in 
biomedical research. 
 
The laws of many states welcome these principles. Spain, for example, passed 
the Biomedical Research Act of July 3, 2007
4
, which is one of the first laws that was  
enacted by the States of the Council of Europe following the adoption of the Additional 
Protocol on Biomedical Research of 25 January 2005 of the Convention on Human 
Rights and Biomedicine of 4 April 1997
5
. 
 
In the UK and in the U.S. the critical issue in respect to ethics and law is the 
research concerning pre-embryos, embryos and fetuses. To solve this problem Spain 
adopted a permissive approach that appears in the Biomedical Research Act, which has 
generated a lot of controversy, not only on ethical grounds but also on constitutional 
aspects. 
 
II. PRINCIPLES GUIDING HUMAN SUBJECT RESEARCH IN SPANISH LEGISLATION 
 
Unlike the Charter of Fundamental Rights of the European Union (Article 3),
6
 
the Spanish Constitution does not specifically refer to biomedical research. 
Nevertheless, the Constitution is clearly in harmony with the U.S. concept of 
principlism, addressing the majority of the fundamental rights on which this method is 
based, including the dignity of the individual, the right to life and to physical and moral 
integrity, freedom of thought or conscience, the right to privacy, freedom from 
discrimination based on race or sex, and the right to protect scientific and technical 
inventions (Cruz Villalón 2006; Romeo Casabona 2002: pp. 1-2). All of these are 
present in the Belmont Report,
7
 which was highly influential not only in the United 
States commencing with the work of T. L. Beauchamp and J. F. Childress (2013) but 
also in many other countries, in the work of many NGOs and the most significant 
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international organizations for the protection of human rights, such as the Council of 
Europe and UNESCO, setting forth the ethical principles for addressing the problems 
that arise from biomedical research (Jonsen 1994: pp. 13-21). Principlism is universal in 
nature. It is inevitably applied in a diversity of cultures, religious beliefs and political 
systems.
8
 A common medical ethic is needed in the treatment and prevention of human 
diseases, where the four great principles of bioethics play an essential role (Preston 
1994: pp. 23-30). 
 
Principlism is reflected in professional codes of conduct and ethics, which in 
turn have influenced international instruments dealing with biomedical research, such as 
the Convention for the Protection of Human Rights and Dignity of the Human Being 
with regard to the Application of Biology and Medicine (Convention on Human Rights 
and Biomedicine) of April 4, 1997
9
 and its Additional Protocol concerning Biomedical 
Research of January 25, 2005, as well as the Universal Declaration on Bioethics and 
Human Rights of October 19, 2005. The basic principles set forth in these instruments 
have been accurately reflected in the domestic laws of many countries. Spain’s laws 
reflect the principlism, noting that the key issues relate to the grounds and the 
hierocracy of these principles. They give structure to application in biomedicine and are 
essential in adopting rigorous ethical decisions by the medical professionals and other 
health sciences (Gafo 1998: pp. 106-111; Gracia 1989: pp. 99-104; 182-197; 285-293; 
Castellano 1998: pp. 31-36). The law establishes the principles and guarantees that need 
to be respected by biomedical research on humans (Silveira 2008: p. 24). The 
Biomedical Research Act of July 3, 2007 is influenced by these principles
10
. 
 
The principles set forth in these international instruments are present in recent 
Spanish legislation governing biomedical research due to the fact that they have been 
strongly influenced by the Convention on Human Rights and Biomedicine and its 
Additional Protocol concerning biomedical research, as well as by U.K. and U.S. 
legislation and practice. Spanish legislation in this area includes the Royal Decree of 
February 6, 2004 Regulating Clinical Trials with Medicines; the Medicines and Health 
Products (Guarantees and Rational Use) Act of July 26, 2006; the Order of the Ministry 
of Health and Consumer Affairs of February 5, 2007 Regulating Research on Medicines 
for Human Use; and the Biomedical Research Act of July 3, 2007. 
 
The importance of research on medicines and health products explains why the 
first legal provisions in Spain concerning biomedical research were passed to regulate 
clinical trials with drugs. Royal Decree of February 6, 2004 Regulating Clinical Trials 
with Medicines
11
 transposed into Spanish law Directive 2001/20/EC relating to the 
Implementation of Good Clinical Practice in the Conduct of Clinical Trials on 
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Medicinal Products for Human Use (the “Clinical Trials Directive”) within the scope of 
the European Union. The Royal Decree is modeled on principles governing clinical 
trials in human subjects set forth in the Declaration of Helsinki and the Convention on 
Human Rights and Biomedicine, as well as legislation protecting personal data, 
including the Spanish Personal Data Protection Act (Organic Law of December 13, 
1999).
12
 
  
Pursuant to the Royal Decree Regulating Clinical Trials with Medicines, a 
clinical trial may only be commenced when the Clinical Trials Ethics Committee and 
the Spanish Medicines and Health Products Agency consider that the benefits for the 
trial participants and society in general justify the risks. Clinical trials must be 
conducted according to the standards of good clinical practice published by the Ministry 
of Health and Consumer Affairs, which are binding upon the sponsor, monitor and 
investigator.
13
 Compliance with these standards is verified through inspections carried 
out by the Spanish Agency for Medicines and Health Products, as well as the health 
authorities of the Autonomous Communities within the scope of their respective 
powers.
14
 The physical and mental integrity of subjects, as well as their privacy and the 
confidentiality of their personal data must be guaranteed. Each clinical research 
participant must freely give his informed consent in writing before being included in the 
trial.
15
 The informed consent of a legal representative is required for participating 
minors or incapacitated adults. At any time, research subjects or their legal 
representatives may revoke their consent without detriment of any kind.
16
 As a general 
rule, clinical trials with investigational drugs cannot be conducted unless an insurance 
policy or other financial guarantee has been previously subscribed to cover damages in 
the event of injuries to participants that may arise as a result of the trials. If no insurance 
or other financial guarantee has been provided, or if they do not entirely cover the 
damages claimed, the sponsor of the clinical trial, the primary investigator and the 
hospital where the trial is conducted shall share joint and several strict liability for any 
impairment in the health of a trial subject, including economic loss, likewise bearing the 
burden of proving that they are not the consequence of the clinical trial or the 
therapeutic or diagnostic measures taken during the course thereof. In these 
circumstances, neither administrative authorization nor the favorable opinion of the 
Clinical Trials Ethics Committee will enable the sponsor of the clinical trial, the 
primary investigator and his collaborators, or the hospital or institution where the trial is 
conducted to disclaim liability. Unless otherwise proven, it is assumed that impairment 
to a subject’s health during the course of a clinical trial and for one year thereafter is the 
result of the trial. However, after a year the subject is required to prove the causal nexus 
between the clinical trial and the impairment sustained. Liability for compensation 
includes all expenses derived from any impairment in the clinical trial subject’s health 
or physical state, including any directly-derived economic loss, provided that such 
impairment is not inherent in the pathology under study, is not among the adverse 
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reactions to the medication prescribed for that pathology, or is not simply part of the 
evolution of the illness in question as a result of the ineffectiveness of the treatment. 
The minimum liability guaranteed per clinical trial subject is 250,000 euros, as lump 
sum compensation.  
 
Clinical Trials Ethics Committees play a fundamental role in evaluating the 
methodological, ethical and legal aspects of the clinical trials submitted to them and 
assessing any relevant changes in the trials initially authorized, as well as overseeing 
trials from their commencement until their final reports are submitted.
17
 Sponsors must 
likewise apply to the Director of the Spanish Medicines and Health Products Agency for 
authorization to conduct their clinical trials.
18
 The Agency may resolve to suspend or 
revoke a trial on its own initiative or upon a justified petition from the sponsor, if the 
trial contravenes the law, if the conditions under which it was authorized change, or due 
to noncompliance with the ethical principles designed to protect clinical trial subjects 
and ensure public health.
19
 Upon termination of the trial, the sponsor must notify the 
Agency and the Ethics Committees of that fact within ninety days.
20
 Failure to comply 
with these obligations constitutes an administrative infraction and carries the 
corresponding sanctions set forth in the Medicines and Health Products (Guarantees and 
Rational Use) Act of July 26, 2006.
21
 
 
The fundamental guarantees contained in the Royal Decree Regulating Clinical 
Trials with Medicines are likewise reflected in the Medicines and Health Products 
(Guarantees and Rational Use) Act of July 26, 2006. This law provides four guarantees 
to ensure that clinical trials are conducted satisfactorily, while protecting the 
fundamental rights of trial subjects. First there are guarantees of suitability, which 
ensure that clinical trials on investigational drugs are submitted for approval by the 
Spanish Medicines and Health Products Agency.
22
 The public health authorities have 
powers to inspect clinical trials,
23
 ensuring compliance with standards of good clinical 
practice.
24
 Trials must adhere to the content of the specific research protocol for which 
authorization was granted, and any subsequent changes.
25
 All clinical trial results, 
whether positive or negative, must be reported to the Spanish Medicines and Health 
Products Agency, without prejudice to likewise notifying the authorities of the 
Autonomous Communities in which the research was conducted.
26
 
 
The second guarantee concerns ethical principles, according to which clinical 
trials must respect the fundamental rights of trial participants and those affecting 
biomedical research in human subjects, which reflect the content of the Declaration of 
                                                 
17
 Article 10 as it relates to Articles 11-14. 
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21
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22
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ETHICS AND LEGAL KEYS TO BIOMEDICAL RESEARCH IN SPAIN 
 
The Age of Human Rights Journal, 2 (June 2014) pp. 51-67  ISSN: 2340-9592 
 
56 
Helsinki.
27
 A third guarantee entails assumption of liability, whereby clinical trials will 
require an insurance policy or other financial surety to ensure coverage for any claim for 
damages that may derive from the research undertaken.
28
 As was the case with the 
Clinical Trials Regulation, if for any reason the insurance does not totally cover the 
injuries caused, the sponsor of the trial, the primary investigator and the hospital or 
institution where the trial was conducted shall share joint and several strict liability, and 
shall bear the burden of proof. Neither administrative authorization of the trial nor the 
opinion of the Clinical Trials Ethics Committee will enable them to disclaim this 
liability.
29
 Unless proven otherwise, impairment to the health of participants sustained 
during the trial and up to one year thereafter is deemed to be a result of the trial. 
However, after a year the trial subject must prove the nexus between the trial and the 
impairment sustained.
30
 A fourth guarantee concerns transparency in clinical trials, 
which must be entered on a National Register of Clinical Trials that is public and may 
be freely accessed.
31
 The sponsor is likewise obliged to publish both positive and 
negative results. To ensure compliance with these guarantees, there is a system for 
inspecting and ordering provisional remedies, and heath authorities carry out the 
necessary inspections within the scope of their powers.
32
 After the pertinent 
investigation, failure to comply with these obligations will be subject to administrative 
sanctions, without prejudice to any civil, criminal or other liability which the 
nonconforming party may incur. 
 
The Ministry of Health Order of February 5, 2007,
33
 setting forth the specific 
principles and directives of good clinical practice and the standards for authorizing the 
manufacture and import of investigational drugs for human use incorporates into 
Spanish law the European Union “Good Clinical Practice Directive” 2005/28/EC. As 
indicated in its Preamble, this Order was issued pursuant to the Second Final Provision 
of the Royal Decree of February 6, 2004 regulating clinical trials with medicines. 
 
In a manner similar to the aforementioned provisions, this Order regulates the 
principles and directives for good clinical practice in clinical trials with investigational 
drugs for human use, the requisites for authorizing the manufacture and import of those 
medicines, detailed instructions on trial documentation and records, and the 
qualification of inspectors and inspection procedures. 
 
III. THE BIOMEDICAL RESEARCH ACT OF JULY 3, 2007 
 
The Biomedical Research Act of July 3, 2007 (Beauchamp and Childress 201; 
Beauchamp 1994; Ainslie 2003) incorporates into Spanish law the principles contained 
in the Convention on Human Rights and Biomedicine and its Additional Protocol, 
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regulating research on human subjects. Other laws, such as the Patient Autonomy 
(Clinical Information and Documentation Rights and Responsibilities) Act of November 
14, 2002
34
 and the Personal Data Protection Act of December 13, 1999, may be applied 
subsidiarily, provided that they are not in conflict with the Biomedical Research Act
35
. 
This law also repealed several other provisions in this area.
36
 
 
This Act lends full respect to human dignity and identity rights of the individual, 
with respect to biomedical research, whether it be basic or clinical research
37
, except in 
clinical trials with medicines and health products
38
. Such trials are allowed during 
pregnancy and lactation, and in persons unable to consent because of their clinical 
condition
39
. Biomedical research on embryos, fetuses, oocytes and preembryos is also 
supported, which has always been a contentious issue
40
. 
 
Literature in both the U.K. and the U.S. clearly distinguishes between the 
embryo and the human fetus. J. M. Harris, D. Morgan and M. Ford affirm that 
scientifically the product of conception is called “embryo” until the eighth week of 
gestation. From that moment, the term changes and it is referred to as a “fetus.” In 
practice, an embryo as the subject of research is the laboratory embryo, which is usually 
the result of in vitro fertilization (IVF). Moreover, within the category of embryo, a 
variety of terms are used: preembryo, preimplantation embryo, ex utero embryo and 
premature embryo (Harris, Morgan, and Ford 2003). With regard to embryo research, 
the fourteen-day term is essential, as was underscored in the United Kingdom in the 
Warnock Report of 1984. However, some authors suggest that justification for the 
fourteen-day limit is not convincing and propose extending the limit for research with 
embryos fertilized in vitro to thirty-eight days.
41
 One of the reports of the President’s 
Council on Bioethics underscores the increased capacity to intervene in the beginnings 
of human life, especially life outside the body, whether in the clinic or the laboratory, 
which has given rise to huge advances in biotechnology in recent decades. This 
capacity, which emerges from a confluence of work in reproductive biology, 
developmental biology and human genetics, has raised ethical issues involving a 
                                                 
34
 Official State Gazette no. 274 (15 November 2002). 
35
 Second Final Provision of the Biomedical Research Act. 
36
 Law 42/1988 of December 28 (Donation and Use of Human Embryos and Fetuses or their Cells, Tissue 
or Organs Act) and any provisions of any rank that are contrary to the provisions of this Law. Likewise 
repealed are: paragraphs 5 and 6 of Article 45 and Articles 46, 47 and 50 of Law 16/2003 of May 28 
(National Health System Cohesion and Quality Act); Title VII and Chapters II and III of Title VI of Law 
14/1986 of April 25 (General Health Act); the Second Additional Provision of Law 14/2006 of May 26 
(Human Assisted Reproduction Techniques Act); and Articles 10 and 11 of the Bylaws of the National 
Center for Transplants and Regenerative Medicine passed by Royal Decree 176/2004 of 30 January (Sole 
Repeal Provision. Legislative Repeal). 
37
 Article 1.1. 
38
 Article 1. 3. 
39
 Articles 19 and 20. 
40
 De Miguel Beriain, 2004: p. 358; Ruiz de la Cuesta 2012: pp. 23-39; Casonato and Penasa 2012: pp. 
41-65; Ferrajoli 2011: pp. 729-744; Díaz Revorio 2011: pp. 789-826; Rivera López 2011: pp. 1065-1094; 
Gascón Abellán 2011: pp. 1095-1121. 
41
 Edwards 1989 (Cfr. Walters, L. (revised by A. Drapkim Lyerly) (2003)) 
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number of important human goods.
42
 It is not surprising that many of the technological 
applications in this field are controversial. The origins of these controversies are rooted 
in different criteria concerning the diverse interests at stake and the weight to be given 
each of them: reproductive freedom, prenatal life, the status of embryos and freedom of 
scientific research, among many others. These interests are perceived and valued in 
many different ways in plural societies such as the United States. The President’s 
Council on Bioethics has affirmed that there is profound disagreement in U.S. society 
concerning the degree of respect owed in vitro human embryonic life and its relation to 
other moral considerations such as helping infertile couples have healthy children and 
advancing biomedical knowledge that might lead to cures for terrible diseases.
43
 
 
In that regard, the United Kingdom has adopted criteria that place few limits on 
the application of assisted reproduction techniques and biomedical research with 
preembryos, implementing solutions that are more permissive than those presently 
existing in the United States and other countries.
44
 The regulation of assisted 
reproduction and embryo research came to the forefront with the publicity surrounding 
the birth of Louise Brown. The 1984 Warnock Report recommended regulating assisted 
reproduction and authorizing research with embryos created in vitro for up to fourteen 
days after fertilization. Based on the Warnock Report, the Human Fertilisation and 
Embrylogy Act (HFEAct) was passed in 1990 to set up the necessary requisites and 
controls. Research protocols were initially limited to studying infertility and the causes 
of congenital defects, as well as to identifying abnormal genes or chromosomes in 
embryos (Walters (revised by A. Drapkim Lyerly) 2003: p. 925). In a statutory 
instrument of January 24, 2001, Parliament amended the HFEAct to permit embryo 
research to increase knowledge to be applied in developing treatment for serious 
disease. In 2003 the House of Lords further increased the scope of the HFEAct to 
include all types of embryos, not only those created by fertilization of eggs by sperm. 
Thus, the Human Fertilisation and Embryology Authority (HFEA), created in 1991, 
assumed the powers to authorize research with embryos created by means of nuclear 
transfer, as well as through fertilization with sperm (Harris, Morgan, and Ford 2003: p. 
507). And on May 17, 2007 the British government authorized the creation of inter-
species embryos for disease research purposes, provided that they are destroyed after 
fourteen days of development and are never implanted in a uterus. The authorization of 
this new procedure can be explained by the fact that, in contrast to the immense 
majority of countries, the creation of human embryos for research purposes has been 
permitted since 2004. The decision was the result of pressure from scientific groups 
faced with a severe shortage of human eggs for use in research. The HFEA must 
analyze each individual application, and issues its authorization only for a single line of 
research. An initial research project with hybrid embryos has already been conducted 
(Jha 2008). 
 
                                                 
42
 The President’s Council on Bioethics, Reproduction & Responsibility. The Regulation of New 
Tecnologies, Washington, D. C. (2004) XXXIX. 
43
 Id., 8. 
44
 For an excellent analysis of historical and ideological aspects of legislative options in the United States, 
United Kingdom and Germany, see Belew 2003-2004: pp. 479, 486, 496, 507. 
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Pursuant to the NIH Revitalization Act of 1993, the United States Congress 
authorized the National Institutes of Health (NIH) to finance research using assisted 
reproduction techniques to increase the knowledge and treatment of infertility. Research 
authorized by Congress included the use of human embryos. Recognizing the 
controversies surrounding such research, the NIH decided that an analysis of ethical 
aspects was warranted prior to financing any of the proposed projects. For that purpose, 
the NIH turned to the Human Embryo Research Panel (HEPR), in charge of providing 
advice and recommendations in this field. The HEPR considered the moral status of 
embryos and the ethical standards governing research with human subjects. It affirmed 
that although the pre-implantation human embryo warrants serious moral consideration 
as a developing form of human life, it does not have the same moral status as infants or 
children.
45
 This conclusion implies that pre-implantation embryos are not fully human 
beings, and thus do not warrant protection as such. Based on this determination, certain 
research projects that may result in the destruction of embryos have been considered 
acceptable for federal funding. However, the HEPR affirmed that human embryos 
deserve “serious moral consideration” and should be accorded treatment different from 
that given mere human cells or animal embryos. In that regard, the HEPR proposed 
restrictions on embryo research based on moral considerations. Thus, human embryos 
should be used in research only as a last resort, the number of embryos used should be 
limited and embryos should not be allowed to develop beyond the time required in the 
specific research protocol and never beyond the fourteen-day limit. Applying ethical 
standards governing research on human subjects, the HEPR invoked criteria used by 
Institutional Review Boards (IRBs). Egg, sperm and embryo donors must be informed 
of the specific purposes of the projected research, as well as its procedures and risks. 
Despite President Clinton’s directing the NIH not to finance the creation of embryos 
solely for research purposes, the majority of research involving in vitro fertilization and 
human embryos is federally funded. Moreover, Congress changed its previous position 
and prohibited the NIH from financing any project that damages or destroys human 
embryos. In recent years the ethical and political debate concerning research with 
“spare” embryos from in vitro fertilization treatments has intensified. Some authors 
have proposed restrictive criteria, opposing any research with embryonic stem cells 
resulting in the death of the embryo, which is considered a human being. The Catholic 
Church’s position is particularly clear in that regard. In line with the dominant position 
in the United Kingdom, others think that obstacles should not be placed on this type of 
research, considering that embryos cannot be deemed human until at least fourteen days 
after fertilization,
46
 and that there should be no objection to the creation of embryonic 
stem cell banks (Ecker and O’Rourke 2007: pp. 48-50; Lott and Savulesco 2007: pp. 
37-44). 
                                                 
45
 “Human Embryo Research Panel, National Institute of Health,” Report of the Human Embryo Research 
Panel, Vol. 1, Washington D. C. (1994) X. 
46
 The debate is extraordinarily intense in the United States in which there is a confluence of scientific, 
ethical, religious, economic and political factors, reflected in an extremely abundant bibliography. 
Presently, this is perhaps the most controversial aspect of bioethics, given that biomedical research 
depends decisively on research with embryonic stem cells. See Steinbock 2006: pp. 26-34; DeGrazia 
2006: pp. 49-57; Gómez-Lobo 2004: pp. 75-79; Johnson 2007: pp. 19-30; Fennel 2008: pp. 84-91; 
McLeod and Baylis 2008: pp. 467-477; Gibson 2008: pp. 370-378; Agar 2008: pp. 198-207. 
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The President’s Council on Bioethics’ Report on Reproduction and 
Responsibility (Washington, D.C: PCB, 2004) recommends legally prohibiting human 
embryo research under certain conditions, and specifically, that embryos not be 
maintained in vitro for more than fourteen days following fertilization. With a view to 
expressly respecting the status of the human embryo, research conditions have been 
established that are much more restrictive than those regulating research with human 
cells or animal embryos. For example, research must be conducted for significant 
scientific or medical objectives, and may only involve the use of human embryos if the 
research cannot be carried out by other means. As a control mechanism, ethics 
committees are to play a fundamental role in ensuring compliance with legal provisions 
governing this type of research (Douglas 2007: pp. 732-736). 
 
In 2007, with a Democratic majority, Congress passed a law facilitating federal 
funding for biomedical research with surplus embryos from in vitro fertilization, with 
the possibility of obtaining embryonic stem cells. President Bush vetoed that legislation, 
considering that it threatens the life of the embryo, having constantly manifested his 
opposition to the unlimited use of embryonic stem cells because it results in the 
destruction of embryos. The intense debate in this area may be largely explained by the 
economic interests involved in the area of biomedical research and, in general, in 
medical practice, as underscored by numerous authors concerned about the “problem of 
commercialism in medicine.
47
 In other respects, two independent teams of Japanese and 
American scientists have obtained pluripotent cells from skin. This research has resulted 
in the discovery of a technique that yields stem cells without the use of human embryos. 
Nevertheless, it is in the early stages and must be further developed to adequately assess 
its potential. 
 
The Spanish Biomedical Research Act sets limits on in utero research with live 
embryos and fetuses. In utero interventions can only be conducted for diagnostic or 
therapeutic purposes in the interest of the embryo or fetus, without prejudice to legal 
provisions for the voluntary interruption of pregnancy.
48
 Research on human embryos 
and fetuses must comply with a series of requisites to ensure that they conform to the 
principles on which the Biomedical Research Act is based. They must be human 
embryos or fetuses that have lost their capacity for biological development, and the 
donor or donors (or their legal representatives in the case of non-emancipated minors or 
incapacitated adults) must have previously given their express informed consent in 
writing. The project detailing the use to be made of the embryos or fetuses must be 
approved by the Oversight Committee for Donations and Use of Human Cells and 
Tissue, as well as the corresponding state or autonomous community authorities. And 
the team in charge of the authorized project must report the results to both the entity that 
authorized the project and the Oversight Committee for Donations and Use of Human 
Cells and Tissue.
49
 Research with pregnant women may only be authorized if it entails 
                                                 
47
 Kassirer 2007: pp. 377-386; Rodwin 2007: pp. 387-397; Churchill 2007: pp. 407-414; Fins 2007: pp. 
425-432. 
48
 Article 30.  
49
 Article 31.  
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only minimum risks for the embryo, fetus or child.
50
 Research with oocytes and 
preembryos is authorized,
51
 provided that consent is obtained from their donors, which 
may be revoked at any time without affecting the research in question.
52
 Oocyte and 
preembryo donation is governed by the provisions of the Human Assisted Reproduction 
Techniques Act of May 26, 2006.
53
 In any case, the creation of human preembryos and 
embryos for research purposes is prohibited.
54
 Nevertheless, within the terms defined in 
the Act, any technique may be employed for obtaining human stem cells for therapeutic 
uses or research, as long as preembryos or embryos are not created exclusively for that 
purpose, including the activation of oocytes through nuclear transfer.
55
 Research and 
experimentation are permitted with surplus oocytes and preembryos, or their biological 
structures, obtained from assisted reproduction treatments, for the purpose of 
harvesting, developing and using embryonic stem cell lines or for other purposes not 
related to the development and application of assisted reproduction techniques. In that 
regard, the conditions set forth in the Human Assisted Reproduction Techniques Act 
must be met, and the research must respect the ethical principles and applicable legal 
precepts, particularly those contained in the Biomedical Research Act and its 
implementing regulations, reflecting the principles of relevance, feasibility and 
suitability.
56
 Authorization is subject to receiving approval from the management of the 
institution where the research is to be conducted, as well as a favorable opinion from the 
corresponding Research Ethics Committee. The project must indicate any relationships 
or common interests of any nature, if any, between the research team and the entity that 
conducted each of the assisted reproduction processes that produced the preembryos or 
that intervened in obtaining the oocytes to be used. The project must likewise contain 
written undertakings to provide the public authorities with data that identify and enable 
monitoring of the conservation of any stem cell lines that may be obtained during the 
research and to provide those stem cell lines free-of-charge for use by other researchers. 
And in the event oocytes or preembryos are used, the project must provide an indication 
and justification of their origin and the number used, as well as informed consent 
documents signed by their respective donors.
57
 
 
The preamble to the Biomedical Research Act underscores that this law governs 
areas that were previously unregulated or only partially covered, given changes in 
recent years, particularly in the areas of genetic analysis, research with human 
biological samples, especially embryonic ones, or biobanks. The Act explicitly prohibits 
the creation of human preembryos and embryos exclusively for research purposes, in 
accordance with the gradualist position with respect to the protection of human life set 
forth by the Constitutional Court in its judgments 53/1985, 212/1996 and 116/1999, but 
                                                 
50
 Article 19 c). 
51
 “Preembryo” is defined in Article 3.s), affirming that it is an embryo created in vitro, formed by a 
group of cells resulting from the progressive division of an oocyte from its fertilization until 14 days 
thereafter. 
52
 Article 32.1. 
53
 Article 32.2. 
54
 Article 33.1. 
55
 Article 33.2. 
56
 Article 35.1. 
57
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it permits the use of any technique for obtaining human stem cells for therapeutic 
purposes or research, providing the preembryo or embryo is not created exclusively for 
that purpose and in the terms set forth in the Act. With regard to the use of surplus 
embryos from human assisted reproduction treatments, the legal framework is set forth 
in the Human Assisted Reproduction Act of May 26, 2006, which expressly prohibits 
so-called human reproductive cloning. 
 
Prior to the enactment of the Biomedical Research Act, efforts were made to 
determine whether research with preembryos was legally admissible (Tur Ausina 2008: 
pp. 789-812). 
 
Commencing with its Judgment 53/1985 of April 11 regarding Article 417 bis of 
the Criminal Code in relation to criminal abortion, the Constitutional Court considered 
the nasciturus not as a person and a subject of fundamental rights, but rather as a 
“constitutional interest” worthy of protection. The Court ruled that the arguments 
alleged by the appellants could not be accepted to support the thesis that the nasciturus 
also has the right to life, but rather that it is a “constitutionally-protectable interest,” and 
that lawmakers must not impede the natural gestation process and must adequately 
protect this legal interest, even with penal laws, when warranted. This case law of our 
Constitutional Court reflects the case law of the European Commission of Human 
Rights in the 1980s, which denied that the concept of person as defined in Article 2 of 
the Council of Europe’s Convention for the Protection of Human Rights and 
Fundamental Freedoms of 1950 applied to the protection of the nasciturus. 
 
This Constitutional Court case law was firmly established in Judgment 212/1996 
of December 19 concerning the Human Embryos and Fetuses (Donation and Use) Act 
42/1988 of December 28 and in Judgment 116/1999 of June 17 on the Human Assisted 
Reproduction Techniques Act 35/1988 of November 22. 
 
Constitutional Court Judgment 212/1996 of December 19 affirms that the 
regulation provided in the Human Embryos and Fetuses (Donation and Use) Act is 
based on the fundamental precept that biomedical research can only be conducted on 
non-viable human embryos and fetuses, case law that was reiterated in Constitutional 
Court Judgment 116/1999 of June 17. 
 
Law 7/2003 of October 20
58
 regulating Research in Andalusia with Human 
Embryos that are Non-viable for In Vitro Fertilization considers that preembryos are no 
longer viable after five years in cryostorage. 
 
Law 45/2003 of November 21,
59
 amending the 1998 Human Assisted 
Reproduction Techniques Act (Law 35/1988 of November 22) addresses the problem of 
surplus embryos. Any use of preembryos in cryostorage prior to the enactment of this 
law must be determined by the couple or woman involved, who may chose between 
                                                 
58
 Official State Gazette no. 279 (21 November 2003). 
59
 Official State Gazette no. 280 (22 November 2003). 
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maintaining them in cryostorage until they are transferred, donating them for 
reproductive purposes, or consenting to the use of the biological structures obtained 
upon thawing for research purposes, within the limits set forth in the law’s Final 
Provision. Royal Decree 2132/2004 of October 29
60
 defines the requisites and 
procedures for research using stem cells obtained from surplus preembryos. 
 
The new Human Assisted Reproduction Techniques Act 2006 (Law 14/2006 of 
May 26
61
) introduced essential changes in the area of biomedical research with human 
embryos from in vitro fertilization by authorizing research or experiments with surplus 
preembryos from assisted reproduction treatments. 
 
The controversy concerning research with oocytes and preembryos involves the 
conflict between both the Human Assisted Reproduction Techniques Act 2006 and the 
Biomedical Research Act 2004 and the case law of the Constitutional Court established 
in Judgments 212/1996 of December 19 and 116/1999 of June 17 whereby research or 
experiments can only be conducted on preembryos if it does not compromise their 
viability, which is not the case when obtaining embryonic stem cells. 
 
Thus the constitutionally-guaranteed protection of human life is violated when 
the harvesting of embryonic stem cells results in the destruction of the preembryo, 
implying a utilitarian concept of the embryo that ignores its status as a human being in 
its initial stage of gestation. The embryo is a live human being in the process of 
development from the moment of fertilization, since from that moment all genetic 
material is present. There is no preembryonic stage, since prior to the embryo the human 
being does not exist, there merely being two sexual cells, the egg and sperm. The term 
“human embryo” is not clearly defined, thus compromising legal certainty, since 
“preembryo” lacks scientific rigor as an autonomous category and its use is not 
authoritative. In effect, “preembryo” is not used in international instruments, and the 
Convention on Human Rights and Biomedicine and its Additional Protocol do not refer 
to “preembryos,” but rather exclusively to “embryos.” There are likewise alternatives to 
the use of embryonic stem cells that do not involve the destruction of embryos. These 
include harvesting umbilical stem cells or the possibility of creating embryonic stem 
cell lines without destroying an embryo, as when they are obtained from skin cells. In 
any event, it will be difficult to reconcile the new laws on human assisted reproduction 
techniques and biomedical research with the Constitutional Court’s case law (Cruz 
Villalón 2006: pp. 25-26) unless embryonic stem cells can be obtained without the 
destruction of embryos. 
 
Having thus outlined the terms of the debate, we can only await the 
Constitutional Court’s response to a possible appeal challenging the constitutionality of 
research with surplus embryos from in vitro fertilization treatments, as authorized in the 
Biomedical Research Act. The Constitutional Court will certainly have to clarify its 
position concerning the protection of the nasciturus and the viability of human embryos. 
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However, it should be noted that in the ample period transpired since the Act was 
passed, there has been no indication that any political group intends to challenge its 
constitutionality, most likely due to significant underlying economic interests, among 
others. 
  
The draft of the Law for the Protection of Life of the Conceived and the rights of 
the pregnant woman amends Organic Law of November 23, 1995 of the Criminal Code, 
which only allows abortion when necessary to prevent a serious threat to life or physical 
or mental health of the pregnant woman, if practiced  within the first twenty weeks of 
gestation, when the pregnancy is the result of an illegal act against sexual freedom or 
indemnity, the abortion is performed within the first twelve weeks of pregnancy and the 
offense must be reported previously (art. 145 bis). If the draft legislation finally 
becomes law, an ethical debate will be launched on research with preembryos in the 
terms allowed by Biomedical Research Law. 
 
As a supplement to the Biomedical Research Act, Patient Autonomy (Clinical 
Information and Documentation Rights and Responsibilities) Act (Law 41/2002 of 
November 14) is applicable in any area that it does not cover.
62
 The Patient Autonomy 
Act does not specifically address biomedical research, although when defining 
interventions within the scope of medical care, it expressly refers to research. With 
regard to its scope of application, it should be noted that it regulates the right to medical 
information,
63
 right to privacy,
64
 and respect for patient autonomy, which is particularly 
reflected in the regulation of informed consent as a fundamental aspect of this law,
65
 as 
well as clinical records and other documents.
66
 
 
The extraordinary importance of biomedical research in Spain in the last few 
years, especially with respect to the use of embryonic stem cells, has resulted in its 
being one of the sectors with the highest level of investments, both public and private, 
particularly on the part of the pharmaceutical industry, as is the case in the United States 
and, in general, in countries in which research in this area is conducted.
67
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